11 58

Cited 0 times in

Therapeutic Efficacy of Spironolactone for Central Serous Chorioretinopathy

Authors
 Jae Yong Han  ;  Yong Joon Kim  ;  Eun Young Choi  ;  Junwon Lee  ;  Ji Hwan Lee  ;  Min Kim  ;  Suk Ho Byeon  ;  Sung Soo Kim  ;  Christopher Seungkyu Lee 
Citation
 YONSEI MEDICAL JOURNAL, Vol.63(4) : 365-371, 2022-04 
Journal Title
YONSEI MEDICAL JOURNAL
ISSN
 0513-5796 
Issue Date
2022-04
MeSH
Adult ; Aged ; Central Serous Chorioretinopathy* / diagnosis ; Central Serous Chorioretinopathy* / drug therapy ; Fluorescein Angiography / methods ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Spironolactone* / therapeutic use ; Tomography, Optical Coherence / methods ; Visual Acuity
Keywords
Central serous chorioretinopathy ; spironolactone ; therapeutics
Abstract
Purpose: To evaluate the therapeutic effects and safety of oral spironolactone (SPRL) in patients with central serous chorioretinopathy (CSC).

Materials and methods: The medical records and imaging data of patients diagnosed with CSC and treated with SPRL were retrospectively reviewed. Central macular thickness (CMT), subretinal fluid (SRF) height, subfoveal choroidal thickness (SFCT), and best-corrected visual acuity (BCVA) at baseline, at 1, 3, and 6 months, and at the last visit after the treatment were analyzed.

Results: In total, 103 patients with 107 eyes were included. The mean age of the patients was 51.5±9.3 years, and 77 (72.0%) were male. The mean follow-up duration was 48.6±40.2 weeks. The mean duration of oral SPRL therapy was 15.5±13.4 weeks. CMT, SRF height, and SFCT improved significantly at 1, 3, and 6 months after SPRL therapy and at the last follow-up. BCVA, however, showed no significant change at any time point. The rate of complete resolution of SRF at 1 month was higher in those with chronic CSC than in those with acute CSC (21.1% vs. 6.0%, respectively). Recurrence occurred in 14 (13.1%) eyes after the complete resolution of SRF. Older age (p=0.001), a greater number of previous intravitreal bevacizumab injections (p=0.006), and poor initial visual acuity (p=0.048) were associated with recurrence. No permanent adverse effects were observed.

Conclusion: Oral SPRL showed therapeutic benefits in patients with CSC in terms of SRF resolution, but relatively frequent recurrence was observed, especially in older patients.
Files in This Item:
T202201165.pdf Download
DOI
10.3349/ymj.2022.63.4.365
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Min(김민) ORCID logo https://orcid.org/0000-0003-1873-6959
Kim, Sung Soo(김성수) ORCID logo https://orcid.org/0000-0002-0574-7993
Kim, Yong Joon(김용준)
Byeon, Suk Ho(변석호) ORCID logo https://orcid.org/0000-0001-8101-0830
Lee, Christopher Seungkyu(이승규) ORCID logo https://orcid.org/0000-0001-5054-9470
Lee, Jun Won(이준원) ORCID logo https://orcid.org/0000-0003-0543-7132
Lee, Ji Hwan(이지환) ORCID logo https://orcid.org/0000-0003-1759-8195
Choi, Eun Young(최은영) ORCID logo https://orcid.org/0000-0002-1668-6452
Han, Jae Yong(한재용)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/188420
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links